Spotlight on Surgery

Roy S. Herbst, MD, PhD
Credits: 0.75 CME / MOC
On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠
Roy S. Herbst, MD, PhD
RMEI Medical Education, LLC

On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Surgery Presentations

Fernanda P. Silveira, MD, MS, FIDSA, FAST
0.75 CME / MOC
RMEI Medical Education, LLC
CMV Perils in Transplant Recipients: Prevention, Resistance, and Safety Considerations – A Care Team Forum℠

CMV Perils in Transplant Recipients: Prevention, Resistance, and Safety Considerations – A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: November 9, 2021
Expires: November 8, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
  • Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities

Activity Description

In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Statement of Educational Need

Although hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) are essential and often lifesaving, they are associated with potentially life-threatening opportunistic infections. Specifically, cytomegalovirus (CMV) infection is one of the most common infectious complications in patients undergoing HCT and SOT. Greater than 50% of solid organ transplant recipients may display evidence of CMV replication, and 10% to 50% may progress to symptomatic disease. CMV increases mortality risk and may cause organ damage even in the absence of obvious CMV disease. Current CMV antiviral treatments are limited by significant hematologic and renal toxicities, as well as resistance. Strategies to overcome these limitations, including novel antiviral therapies, vaccines, and T-cell therapies, offer hope for transplant patients who face the serious threat of CMV.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Merck (Adjudication Committee Member); Evrys, Hookipa, Merck, Oxford Immunotec, Shire/Takeda, Synklino (Consulting Fees); AiCuris, Hookipa, Oxford Immunotec (Contracted Research); Hookipa (Principal Investigator); Merck, Oxford Immunotec, Shire/Takeda (Speaker Bureau).

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has affiliations with ADMA Biologics, Adagio, Ansun, Genentech, Janssen, Merck, Molecular Partners, Oxford Immunotec, Takeda (Consulting Fees); AiCuris, Ansun, Genentech, Janssen, Karius, Merck, Oxford Immunotec, Takeda, Viracor (Contracted Research).

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Takeda (Consulting Fees); Ansun, Gilead, Novartis, Qiagen, Shire, SlieaGen (Contracted Research).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from November 9, 2021 through November 8, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via e-mail at inquiries@pimed.com.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: November 9, 2021
Expires: November 8, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
  • Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities

Activity Description

In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Statement of Educational Need

Although hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) are essential and often lifesaving, they are associated with potentially life-threatening opportunistic infections. Specifically, cytomegalovirus (CMV) infection is one of the most common infectious complications in patients undergoing HCT and SOT. Greater than 50% of solid organ transplant recipients may display evidence of CMV replication, and 10% to 50% may progress to symptomatic disease. CMV increases mortality risk and may cause organ damage even in the absence of obvious CMV disease. Current CMV antiviral treatments are limited by significant hematologic and renal toxicities, as well as resistance. Strategies to overcome these limitations, including novel antiviral therapies, vaccines, and T-cell therapies, offer hope for transplant patients who face the serious threat of CMV.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Merck (Adjudication Committee Member); Evrys, Hookipa, Merck, Oxford Immunotec, Shire/Takeda, Synklino (Consulting Fees); AiCuris, Hookipa, Oxford Immunotec (Contracted Research); Hookipa (Principal Investigator); Merck, Oxford Immunotec, Shire/Takeda (Speaker Bureau).

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has affiliations with ADMA Biologics, Adagio, Ansun, Genentech, Janssen, Merck, Molecular Partners, Oxford Immunotec, Takeda (Consulting Fees); AiCuris, Ansun, Genentech, Janssen, Karius, Merck, Oxford Immunotec, Takeda, Viracor (Contracted Research).

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Takeda (Consulting Fees); Ansun, Gilead, Novartis, Qiagen, Shire, SlieaGen (Contracted Research).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from November 9, 2021 through November 8, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via e-mail at inquiries@pimed.com.

Roy S. Herbst, MD, PhD
0.75 CME / MOC
RMEI Medical Education, LLC
On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Matt L. Kirkland, MD, FACS
0.75 AANA / CME / MOCA
Vindico Medical Education
Reversing Neuromuscular Blockade: Assessing Current and Emerging Therapies for Improved Outcomes

Reversing Neuromuscular Blockade: Assessing Current and Emerging Therapies for Improved Outcomes

Start

Activity Details

Free CME with MOCA/AANA
0.75 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credits
Released: August 31, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the benefits and limitations of current reversal agents including best practices for their use and the value of appropriate monitoring.
  • Apply the latest clinical evidence of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Utilize a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.
  • Utilize best practices for monitoring patients undergoing neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for causing significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been a priority. A new class of drugs—selective relaxant binding agents—may overcome the limitations of cholinesterase inhibitors, quickly reversing both shallow and deep levels of aminosteroid neuromuscular block. In this educational activity, utilizing an interactive infographic format, expert faculty review the benefits as well as the limitations of current and emerging reversal agents; best practices for monitoring patients undergoing neuromuscular blockade; and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Conventional Reversal Agents: Pros and Cons, Best Practices for Monitoring – Cheryl L. Nimmo, DNP, MSHSA, CRNA

Neuromuscular Blockade (NMB) Therapies: Where We Are and Where We Are Going – Anthony L. Kovac, MD

Neuromuscular Blocking Agents (NMBAs): Multidisciplinary Approach to Care – Matt L. Kirkland, MD, FACS

Faculty

Matt L. Kirkland, MD, FACS
Clinical Associate Professor of Surgery
Director Bariatric Surgery Program
Pennsylvania Hospital
Philadelphia, PA

Disclosure: No relevant financial relationships to disclose.


Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure:
Contracted Research: Merck


Cheryl L. Nimmo, DNP, MSHSA, CRNA
Associate Clinical Professor
Program Director Nurse Anesthesia
University of New England
Portland, ME

Disclosure: No relevant financial relationships to disclose.

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthesiology for 0.75 Class A CE credits; Code Number 1041138; Expiration Date 8/30/2022.

AANA designates this program as meeting the criteria for up to 0.50 CE Credits in pharmacology/therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Only 1 attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME with MOCA/AANA
0.75 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credits
Released: August 31, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the benefits and limitations of current reversal agents including best practices for their use and the value of appropriate monitoring.
  • Apply the latest clinical evidence of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Utilize a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.
  • Utilize best practices for monitoring patients undergoing neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for causing significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been a priority. A new class of drugs—selective relaxant binding agents—may overcome the limitations of cholinesterase inhibitors, quickly reversing both shallow and deep levels of aminosteroid neuromuscular block. In this educational activity, utilizing an interactive infographic format, expert faculty review the benefits as well as the limitations of current and emerging reversal agents; best practices for monitoring patients undergoing neuromuscular blockade; and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Conventional Reversal Agents: Pros and Cons, Best Practices for Monitoring – Cheryl L. Nimmo, DNP, MSHSA, CRNA

Neuromuscular Blockade (NMB) Therapies: Where We Are and Where We Are Going – Anthony L. Kovac, MD

Neuromuscular Blocking Agents (NMBAs): Multidisciplinary Approach to Care – Matt L. Kirkland, MD, FACS

Faculty

Matt L. Kirkland, MD, FACS
Clinical Associate Professor of Surgery
Director Bariatric Surgery Program
Pennsylvania Hospital
Philadelphia, PA

Disclosure: No relevant financial relationships to disclose.


Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure:
Contracted Research: Merck


Cheryl L. Nimmo, DNP, MSHSA, CRNA
Associate Clinical Professor
Program Director Nurse Anesthesia
University of New England
Portland, ME

Disclosure: No relevant financial relationships to disclose.

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthesiology for 0.75 Class A CE credits; Code Number 1041138; Expiration Date 8/30/2022.

AANA designates this program as meeting the criteria for up to 0.50 CE Credits in pharmacology/therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Only 1 attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

J. Ross Renew, MD, FASA, FASE
1.0 AANA / CME / MOCA
Vindico Medical Education
Neuromuscular Blockade Reversal: Navigating the Therapeutic Landscape to Achieve Optimal Patient Outcomes

Neuromuscular Blockade Reversal: Navigating the Therapeutic Landscape to Achieve Optimal Patient Outcomes

Start

Activity Details

Free CME/MOCA/AANA
1.0 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credit
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the benefits and limitations of current reversal agents.
  • Examine the best practices for the use of neuromuscular blocking agents, including the value of appropriate monitoring.
  • Assess the most recent evidence regarding the safety and efficacy of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Evaluate the significance of a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been underway. A new class of drugs, selective relaxant binding agents, may overcome the limitations of cholinesterase inhibitors and quickly reverse both shallow and deep levels of aminosteroid neuromuscular block. In this podcast series, expert faculty review the benefits and limitations of current and emerging reversal agents, best practices for monitoring patients undergoing neuromuscular blockade, and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Best Practices for Monitoring Neuromuscular Blockade with J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Benefits and Drawbacks of Conventional Reversal Agents with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA
Current and Emerging NMB Therapies with  J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Significance of a Multidisciplinary Approach for NMBAs with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA

Activity Chair

J. Ross Renew, MD, FASA, FASE
Assistant Professor of Anesthesiology
Mayo Clinic
Jacksonville, FL

Disclosure: Contracted Research (paid to institution): Merck

Faculty

Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure: Speakers Bureau: Mundipharma
Contracted Research: Merck


Richard Pence, CRNA, MHA
Instructor in Anesthesiology, Mayo Clinic College of Medicine
Mayo Clinic
Jacksonville, FL

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthetists for 1.00 Class A CE credits; Code Number 1040742; Expiration Date 6/29/2022.

AANA designates this program as meeting the criteria for up to 0.75 CE Credits in Pharmacology/Therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, complete the posttest, learner assessment and program evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Only one (1) attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOCA/AANA
1.0 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credit
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the benefits and limitations of current reversal agents.
  • Examine the best practices for the use of neuromuscular blocking agents, including the value of appropriate monitoring.
  • Assess the most recent evidence regarding the safety and efficacy of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Evaluate the significance of a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been underway. A new class of drugs, selective relaxant binding agents, may overcome the limitations of cholinesterase inhibitors and quickly reverse both shallow and deep levels of aminosteroid neuromuscular block. In this podcast series, expert faculty review the benefits and limitations of current and emerging reversal agents, best practices for monitoring patients undergoing neuromuscular blockade, and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Best Practices for Monitoring Neuromuscular Blockade with J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Benefits and Drawbacks of Conventional Reversal Agents with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA
Current and Emerging NMB Therapies with  J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Significance of a Multidisciplinary Approach for NMBAs with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA

Activity Chair

J. Ross Renew, MD, FASA, FASE
Assistant Professor of Anesthesiology
Mayo Clinic
Jacksonville, FL

Disclosure: Contracted Research (paid to institution): Merck

Faculty

Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure: Speakers Bureau: Mundipharma
Contracted Research: Merck


Richard Pence, CRNA, MHA
Instructor in Anesthesiology, Mayo Clinic College of Medicine
Mayo Clinic
Jacksonville, FL

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthetists for 1.00 Class A CE credits; Code Number 1040742; Expiration Date 6/29/2022.

AANA designates this program as meeting the criteria for up to 0.75 CE Credits in Pharmacology/Therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, complete the posttest, learner assessment and program evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Only one (1) attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com